Viemed (VMD) Q2 Revenue Rises 15%
Viemed Healthcare (NASDAQ:VMD), a provider of in-home respiratory care services, released its Q2 2025 results on August 6, 2025. The company reported record quarterly revenue (GAAP), growing to $63.1 million (GAAP), though this was narrowly below the analyst consensus of $63.25 million in GAAP revenue. GAAP earnings per share (EPS) reached $0.08, which also slightly missed the GAAP consensus estimate of $0.085. Despite these modest shortfalls, the quarter saw solid year-over-year growth in patient volumes Management raised its full-year 2025 revenue and Adjusted EBITDA (non-GAAP) outlook, in part due to the recent acquisition of Lehan’s Medical Equipment. The overall performance showed disciplined execution, even as gross margin saw some pressure from changes in the company’s service mix.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Viemed Healthcare specializes in delivering respiratory care and related therapy equipment directly to patients at home. The company's main services involve home ventilation, positive airway pressure (PAP) therapy for sleep disorders, and recurring delivery of supplies. These service lines are supported by a network of certified respiratory therapists and a technology-enabled clinical approach.
Source Fool.com
